Observational studyBreast cancer research and treatment2024

Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.

Rodrigo Sánchez-Bayona et al.PubMed ↗Publisher ↗

No numbers read from the abstract.